The Next Evolution of CRT: Treating the Atrium

Heart failure care is evolving. For decades, therapy has focused on the ventricles—but patients with heart failure with preserved ejection fraction (HFpEF) need a new solution. In HFpEF, the left atrium is the silent driver of symptoms, arrhythmias, and clinical decline, yet current device therapies ignore it.

At MaxWell Biomedical, we are pioneering CRT‑A—Cardiac Resynchronization Therapy for the Atrium—to restore atrial function, improve hemodynamics, and modify the course of disease.

Why the Atrium? Why Now?

• HFpEF is a dual-chamber disease—but standard therapies treat only the ventricles.

• Atrial dysfunction drives clinical outcomes, fueling atrial fibrillation (AF), hospitalizations, and reduced quality of life.

• Early intervention at the atrium offers the opportunity to prevent disease progression and restore rhythm without tissue destruction.

Evidence is clear:

• Atrial dysfunction accelerates HFpEF progression

• Loss of atrial contraction worsens ventricular filling and symptoms

• AF and atrial dyssynchrony double the risk of hospitalization and death

  Rhythm360: Intelligent, Multi-Mode CRT‑A

  MaxWell Biomedical’s Rhythm360™ is the first implantable system designed to restore atrial function through non‑destructive, closed‑loop therapy.

  Our system integrates four programmable therapy modes to address the full spectrum of atrial rhythm management:

  1. Prevention – Senses and suppresses AF triggers before they start

  2. Restoration – Painless, imperceptible AF termination without ablation or shocks

  3. LA Reset – Low‑energy atrial cardioversion from within the atrium

  4. BBp (Bachmann’s Bundle pacing) – Restores biatrial synchrony and optimizes AV timing

  Together, these modes deliver continuous, adaptive CRT‑A—sustaining sinus rhythm and preserving atrial transport function.